NASDAQ:AKTX

Akari Therapeutics Stock News

etoro logo Buy AKTX
*Your capital is at risk
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Akari Therapeutics (AKTX
Akari Therapeutics (NASDAQ:AKTX) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of thei
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dum
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacte
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * A
NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose B
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are
As the top-selling drug faces patent scrutiny, Alexion shares continue to underperform despite posting the highest revenue growth in four years. Backed by appro
Previously reported data showed cell-activating receptors for complement-C5a and leukotriene B4 (LTB4) in the retina. Nomacopan inhibits C5a and LTB4 signalling via these receptors. NEW YORK and LON
Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomacopan were.
Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE